Patent US5422362A successfully refreshed from Google Patents.
US5422362A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method to inhibit restenosis
Assignee: Novelion Therapeutics Inc
•
Filing: 1993-07-29
•
Granted: 1995-06-06
•
Expires: 2013-07-29
Abstract
Abstract A method to inhibit the development of intimal hyperplasia following vascular intervention procedures (angioplasty) is disclosed. The method consists essentially of administering a green porphyrin to the subject concurrent with and following the angioplasty. No purposeful irradiation with light absorbed by the green porphyrin is required or employed in the method.
Inventors
- 👤 G. Michael Vincent
- 👤 Patricia M. Logan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 13:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61P; A61P9/00; A61P9/08
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
51 words
A method to inhibit the development of intimal hyperplasia following angioplasty which method comprises administering to a subject in conjunction with said angioplasty an amount of green porphyrin (Gp) effective to inhibit said development, and allowing said inhibition to occur in the absence of irradiation with light absorbed by said Gp.
Claim 2
Independent Claim
51 words
A method to inhibit the development of intimal hyperplasia following angioplasty which method comprises administering to a subject in conjunction with said angioplasty an amount of green porphyrin (Gp) effective to inhibit said development, and allowing said inhibition to occur in the absence of irradiation with light absorbed by said Gp.
Claim 3
Dependent Claim
27 words
The method of claim 1 wherein said administering is conducted by administering 2-5 doses, wherein the first said dose is administered within 6 hours of said angioplasty.
Claim 4
Dependent Claim
15 words
The method of claim 2 wherein said effective amount is 0.01-5 mg/kg in each dose.
Claim 5
Dependent Claim
15 words
The method of claim 3 wherein said effective amount is 0.05-2 mg/kg in each dose.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein said Gp is administered in a liposomal formulation.
Claim 7
Dependent Claim
32 words
The method of claim 1 wherein Gp is of the formula 1-6, as shown in FIG. 1, wherein R 1 , R 2 , R 3 and R 4 are non-interfering substituents.
Claim 8
Dependent Claim
15 words
The method of claim 6 wherein R 1 and R 2 are carbomethoxy and carboethoxy.
Claim 9
Dependent Claim
24 words
The method of claim 6 wherein each R 3 is --CH 2 CH 2 COOH or a salt, amide, ester or acyl hydrazone thereof.
Claim 10
Dependent Claim
21 words
The method of claim 6 wherein Gp is of the formula 3 or 4, wherein R 4 is a non-interfering substituent.
Claim 11
Dependent Claim
20 words
The method of claim 9 wherein said Gp is selected from the group consisting of BPD-DA, BPD-DB, BPD-MA and BPD-MB.
Claim 12
Dependent Claim
10 words
The method of claim 10 wherein said Gp is BPD-MA.
Claim 13
Independent Claim
53 words
A method to inhibit the development of intimal hyperplasia following angioplasty which method consists essentially of administering to a subject in conjunction with said angioplasty an amount of green porphyrin (Gp) effective to inhibit said development, and allowing said inhibition to occur in the absence of irradiation with light absorbed by said Gp.
Claim 14
Independent Claim
53 words
A method to inhibit the development of intimal hyperplasia following angioplasty which method consists essentially of administering to a subject in conjunction with said angioplasty an amount of green porphyrin (Gp) effective to inhibit said development, and allowing said inhibition to occur in the absence of irradiation with light absorbed by said Gp.
Claim 15
Dependent Claim
27 words
The method of claim 12 wherein said administering is conducted by administering 2-5 doses, wherein the first said dose is administered within 6 hours of said angioplasty.
Claim 16
Dependent Claim
15 words
The method of claim 13 wherein said effective amount is 0.01-5 mg/kg in each dose.
Claim 17
Dependent Claim
15 words
The method of claim 14 wherein said effective amount is 0.05-2 mg/kg in each dose.
Claim 18
Dependent Claim
14 words
The method of claim 12 wherein said Gp is administered in a liposomal formulation.
Claim 19
Dependent Claim
32 words
The method of claim 12 wherein Gp is of the formula 1-6, as shown in FIG. 1, wherein R 1 , R 2 , R 3 and R 4 are non-interfering substituents.
Claim 20
Dependent Claim
15 words
The method of claim 17 wherein R 1 and R 2 are carbomethoxy and carboethoxy.
Claim 21
Dependent Claim
24 words
The method of claim 17 wherein each R 3 is --CH 2 CH 2 COOH or a salt, amide, ester or acyl hydrazone thereof.
Claim 22
Dependent Claim
21 words
The method of claim 17 wherein Gp is of the formula 3 or 4, wherein R 4 is a non-interfering substituent.
Claim 23
Dependent Claim
20 words
The method of claim 20 wherein said Gp is selected from the group consisting of BPD-DA, BPD-DB, BPD-MA and BPD-MB.
Claim 24
Dependent Claim
10 words
The method of claim 21 wherein said Gp is BPD-MA.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-05 | 1998-12-05 | 1999-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-05 | 2002-12-05 | 2003-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-05 | 2006-12-05 | 2007-06-06 | $7700.00 | Window Closed / Lapsed |